Stone House Investment Management’s Kymera Therapeutics KYMR Stock Holding History

Stone House Investment Management’s Portfolio KYMR Stock Details KYMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$573	Buy	+5	New	+$430	﹤0.01%	984

Other funds holding KYMR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Stone House Investment Management's KYMR Position: Q2 2026 in Review

Stone House Investment Management opened a new position in Kymera Therapeutics (KYMR) in Q2 2026: 5 shares worth $573. The stake represents ﹤0.01% of the portfolio and ranks #984 among its holdings.

275 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

Stone House Investment Management held 5 shares of Kymera Therapeutics worth $573 as of Q2 2026.
Kymera Therapeutics was a new Stone House Investment Management position in Q2 2026.
Kymera Therapeutics made up ﹤0.01% of Stone House Investment Management's portfolio in Q2 2026, its #984 holding.
275 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Stone House Investment Management's 13F filing for Q2 2026, filed 5 Aug 2026.